Crispr Therapeutics raises $38 mln

Crispr Therapeutics said June 24 that it raised another $38 million in Series B financing, which closes the round at nearly $140 million. Participating investors in this round include Franklin Templeton Investments, New Leaf Venture Partners, funds advised by Clough Capital Partners LP and Wellington Capital Management LLP, and other undisclosed funds specializing in life sciences. Crispr is a biopharmaceutical company.

Source: Business Wire